首页 > 最新文献

Recent patents on biotechnology最新文献

英文 中文
Coronavirus-A Crippling Affliction to Humans. 冠状病毒——人类的一大痛苦。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-04-04 DOI: 10.2174/1872208316666220404103033
Rimple Kaul, S. Devi
Coronaviruses hold idiosyncratic morphological features and functionality. The members of this group have a remarkable capability of infecting both animals and humans. Inimitably, the replication of the RNA genome continues through the set of viral mRNA molecules. Coronaviruses received the least attention until 2003 since they caused only minor respiratory tract illnesses. However, this changed exclusively with the introduction of zoonotic SARS-CoV in 2003. In 2012, MERS-CoV emerged and confirmed this group of viruses as the major causative agents of severe respiratory tract illness. Today, Coronavirus Disease 2019 (i.e., COVID-19) has turned out to be a chief health problem that causes a severe acute respiratory disorder in humans. Since the first identification of COVID-19 in December 2019 in Wuhan, China, this infection has devastatingly spread all around the globe leading to a crippling affliction for humans. The strain is known as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and WHO (the World Health Organization) has termed this new pandemic disease as Coronavirus Disease (COVID-19). COVID-19 is still spreading, with an estimated 136 million confirmed cases and more than 2.94 million deaths worldwide so far while the pandemic is still going on. In the current scenario, there is no particular treatment for COVID-19, however remarkable efforts for immunization and vaccine development can be observed. Therefore, the execution of precautions and proper preventive measures are indispensable to minimize and control the community transmission of the virus. This review summarizes information about the pathophysiology, transmission, symptoms, and the host defense mechanism as well as immunization and vaccine development against COVID-19.
冠状病毒具有独特的形态特征和功能。这个群体的成员具有感染动物和人类的非凡能力。毫无疑问,RNA基因组的复制通过一组病毒信使核糖核酸分子继续进行。直到2003年,冠状病毒受到的关注最少,因为它们只引起轻微的呼吸道疾病。然而,这种情况完全随着2003年人畜共患严重急性呼吸系统综合征冠状病毒的引入而改变。2012年,MERS-CoV出现并证实这组病毒是严重呼吸道疾病的主要病原体。今天,2019冠状病毒病(即新冠肺炎)已被证明是导致人类严重急性呼吸系统疾病的主要健康问题。自2019年12月在中国武汉首次发现新冠肺炎以来,这种感染已在全球范围内毁灭性地传播,导致人类遭受严重痛苦。该毒株被称为严重急性呼吸综合征冠状病毒2(SARS-CoV-2),世界卫生组织将这种新的大流行性疾病称为冠状病毒病(新冠肺炎)。新冠肺炎仍在传播,到目前为止,全球确诊病例估计为1.36亿例,死亡病例超过294万例,而疫情仍在继续。在目前的情况下,新冠肺炎没有特殊的治疗方法,但可以观察到在免疫和疫苗开发方面做出的显著努力。因此,采取预防措施和适当的预防措施对于最大限度地减少和控制病毒的社区传播是必不可少的。这篇综述总结了有关新冠肺炎的病理生理学、传播、症状、宿主防御机制以及免疫和疫苗开发的信息。
{"title":"Coronavirus-A Crippling Affliction to Humans.","authors":"Rimple Kaul, S. Devi","doi":"10.2174/1872208316666220404103033","DOIUrl":"https://doi.org/10.2174/1872208316666220404103033","url":null,"abstract":"Coronaviruses hold idiosyncratic morphological features and functionality. The members of this group have a remarkable capability of infecting both animals and humans. Inimitably, the replication of the RNA genome continues through the set of viral mRNA molecules. Coronaviruses received the least attention until 2003 since they caused only minor respiratory tract illnesses. However, this changed exclusively with the introduction of zoonotic SARS-CoV in 2003. In 2012, MERS-CoV emerged and confirmed this group of viruses as the major causative agents of severe respiratory tract illness. Today, Coronavirus Disease 2019 (i.e., COVID-19) has turned out to be a chief health problem that causes a severe acute respiratory disorder in humans. Since the first identification of COVID-19 in December 2019 in Wuhan, China, this infection has devastatingly spread all around the globe leading to a crippling affliction for humans. The strain is known as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and WHO (the World Health Organization) has termed this new pandemic disease as Coronavirus Disease (COVID-19). COVID-19 is still spreading, with an estimated 136 million confirmed cases and more than 2.94 million deaths worldwide so far while the pandemic is still going on. In the current scenario, there is no particular treatment for COVID-19, however remarkable efforts for immunization and vaccine development can be observed. Therefore, the execution of precautions and proper preventive measures are indispensable to minimize and control the community transmission of the virus. This review summarizes information about the pathophysiology, transmission, symptoms, and the host defense mechanism as well as immunization and vaccine development against COVID-19.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42392132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Meet the Editorial Board Member 会见编辑委员会成员
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-04-01 DOI: 10.2174/187220831601220408113712
E. Jirillo
Emilio Jirillo has been a full professor of immunology at the University of Bari Medical School (Bari, Italy) since 1986. His current fields of interest are mucosal immunity, microbial immunity, and immunonutrition. Especially in the field of immunonutrition, he has recently published in vitro and in vivo studies on the anti-inflammatory effects of polyphenols. He is the author of more than 560 papers, among which, 326 scientific papers are listed in PUBMED, including complete books and some chapters of books. He is the editor-in-chiefof Clinical Immunology Endocrine Metabolic Drugs and Endocrine Metabolic Immune Disorders-Drug Targets.
Emilio Jirillo自1986年以来一直是巴里大学医学院(意大利巴里)免疫学的正式教授。他目前感兴趣的领域是粘膜免疫、微生物免疫和免疫营养。特别是在免疫营养领域,他最近发表了多酚抗炎作用的体外和体内研究。他是560多篇论文的作者,其中326篇科学论文被列入PUBMED,包括完整的书籍和一些章节的书籍。他是临床免疫学、内分泌代谢药物和内分泌代谢免疫疾病药物靶点的主编。
{"title":"Meet the Editorial Board Member","authors":"E. Jirillo","doi":"10.2174/187220831601220408113712","DOIUrl":"https://doi.org/10.2174/187220831601220408113712","url":null,"abstract":"Emilio Jirillo has been a full professor of immunology at the University of Bari Medical School (Bari, Italy) since 1986. His current fields of interest are mucosal immunity, microbial immunity, and immunonutrition. Especially in the field of immunonutrition, he has recently published in vitro and in vivo studies on the anti-inflammatory effects of polyphenols. He is the author of more than 560 papers, among which, 326 scientific papers are listed in PUBMED, including complete books and some chapters of books. He is the editor-in-chiefof Clinical Immunology Endocrine Metabolic Drugs and Endocrine Metabolic Immune Disorders-Drug Targets.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41509229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence and Updates on non-dairy synbiotic beverage development. 非乳制品合生元饮料开发的证据和最新进展。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-03-03 DOI: 10.2174/1872208316666220303095807
Rhaissa Coelho Andrade, Caroline Santana Figueredo, Janaína de Carvalho Alves, M. N. Roselino
BACKGROUNDWith the increase in cases of intolerance and allergies to milk protein, new food possibilities have been studied as an alternative to dairy drinks in order to meet the needs of this population, such as, non-dairy synbiotic drinks.OBJECTIVEThe aim of this study was to carry out an integrative literature review on the main types of non-dairy synbiotic beverages, in order to investigate the probiotics and prebiotics added to them. Besides, we also looked into the characteristics of the substrates and fermentation conditions (temperature, time and pH), to assess the influences on bacterial viability, consumer acceptance, conservation and antimicrobial action.METHODSWe conducted an integrative review of articles published on Pubmed, Web of Science, Scielo, Scopus and Capes journal in the last five years, using the following terms: symbiotic drink, symbiotic beverage, synbiotic drink, synbiotic beverage, bebida simbiótica, not kombucha, which after reading, resulted in the inclusion of 28 articles.RESULTSAs expected, the main probiotics used were from the genera Lactobacillus and Bifidobacterium, and the prebiotics were inulin and fructooligosaccharide. It is noteworthy that all analyzed beverages were in fact probiotics since they obtained values above the minimum viability of 6 log CFU / mL, consequently, they can bring benefits to consumers.CONCLUSIONThus, beyond fruits and vegetables being rich sources of nutrients, they also enable the development of synbiotic drinks delivered from their substrates, being an alternative for the public with restrictions to milk.
背景随着对牛奶蛋白不耐受和过敏病例的增加,为了满足这一人群的需求,人们研究了新的食物替代乳制品饮料的可能性,例如非乳制品合生元饮料。目的本研究旨在对主要类型的非乳制品合生元饮料进行综合文献综述,以研究其添加的益生菌和益生元。此外,我们还研究了底物的特性和发酵条件(温度、时间和pH),以评估对细菌活力、消费者接受度、保存和抗菌作用的影响。方法我们对过去五年中发表在Pubmed、Web of Science、Scielo、Scopus和Capes杂志上的文章进行了综合综述,使用了以下术语:共生饮料、共生饮料、合生元饮料、合生元饮料、bebida simbiótica,而不是康普茶,经过阅读,共收录了28篇文章。结果预期使用的主要益生菌来自乳酸杆菌属和双歧杆菌属,益生元为菊粉和低聚果糖。值得注意的是,所有分析的饮料实际上都是益生菌,因为它们获得的值高于6 log CFU/mL的最低生存能力,因此,它们可以给消费者带来好处。结论因此,除了水果和蔬菜是丰富的营养来源外,它们还能够开发出从其基质中提供的合生元饮料,成为公众对牛奶有限制的替代品。
{"title":"Evidence and Updates on non-dairy synbiotic beverage development.","authors":"Rhaissa Coelho Andrade, Caroline Santana Figueredo, Janaína de Carvalho Alves, M. N. Roselino","doi":"10.2174/1872208316666220303095807","DOIUrl":"https://doi.org/10.2174/1872208316666220303095807","url":null,"abstract":"BACKGROUND\u0000With the increase in cases of intolerance and allergies to milk protein, new food possibilities have been studied as an alternative to dairy drinks in order to meet the needs of this population, such as, non-dairy synbiotic drinks.\u0000\u0000\u0000OBJECTIVE\u0000The aim of this study was to carry out an integrative literature review on the main types of non-dairy synbiotic beverages, in order to investigate the probiotics and prebiotics added to them. Besides, we also looked into the characteristics of the substrates and fermentation conditions (temperature, time and pH), to assess the influences on bacterial viability, consumer acceptance, conservation and antimicrobial action.\u0000\u0000\u0000METHODS\u0000We conducted an integrative review of articles published on Pubmed, Web of Science, Scielo, Scopus and Capes journal in the last five years, using the following terms: symbiotic drink, symbiotic beverage, synbiotic drink, synbiotic beverage, bebida simbiótica, not kombucha, which after reading, resulted in the inclusion of 28 articles.\u0000\u0000\u0000RESULTS\u0000As expected, the main probiotics used were from the genera Lactobacillus and Bifidobacterium, and the prebiotics were inulin and fructooligosaccharide. It is noteworthy that all analyzed beverages were in fact probiotics since they obtained values above the minimum viability of 6 log CFU / mL, consequently, they can bring benefits to consumers.\u0000\u0000\u0000CONCLUSION\u0000Thus, beyond fruits and vegetables being rich sources of nutrients, they also enable the development of synbiotic drinks delivered from their substrates, being an alternative for the public with restrictions to milk.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45997925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Use of patent information to characterize trends in the therapeutic applications of extracellular vesicles derived from mesenchymal stem cells (MSC-EVs). 利用专利信息描述间充质干细胞(msc - ev)衍生的细胞外囊泡治疗应用的趋势。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-03-03 DOI: 10.2174/1872208316666220303095217
Ángela Ponce-Polo, Alvaro RitoréHidalgo, Arturo Argüello Martínez, Roke Iñaki Oruezabal Guijarro
Extracellular vesicles derived from mesenchymal stromal cells (MSC-EVs) are gaining interest for medical purposes. The promising therapeutic effects exhibited in both preclinical and clinical studies suggest that they may become an alternative for certain applications to cell-based therapies, which are subjected to stricter regulations. The commercial exploitation of these candidates requires a proper patent strategy from both the industry and public research organizations. Here, we raise a global patent literature analysis to identify key players and therapeutic applications in the field. Our results show an increasing rate of patent publications since 2009, with Asia (specifically China) leading the patenting activity. The therapeutic use of MSC-EVs within patent literature covers a wide range of diseases, in which "Dermal and Wounds", "Neurology" and "Cardiovascular" are the main therapeutic areas. Moreover, most of these patents include "product-by-process" claims, since the therapeutic effects of MSC-EVs could be influenced by their manufacturing process. Our results follow scientific and clinical literature trends.
来源于间充质基质细胞(msc - ev)的细胞外囊泡在医学上越来越受到关注。在临床前和临床研究中显示出的有希望的治疗效果表明,它们可能成为某些应用的替代细胞疗法,细胞疗法受到更严格的监管。这些候选药物的商业利用需要工业界和公共研究机构制定适当的专利战略。在这里,我们提出了一个全球专利文献分析,以确定在该领域的关键参与者和治疗应用。我们的研究结果显示,自2009年以来,专利发表率不断上升,亚洲(特别是中国)的专利活动处于领先地位。在专利文献中,msc - ev的治疗用途涵盖了广泛的疾病,其中“皮肤和伤口”、“神经病学”和“心血管”是主要的治疗领域。此外,由于msc - ev的治疗效果可能受到其制造工艺的影响,这些专利中的大多数包括“逐工艺产品”的权利要求。我们的结果遵循科学和临床文献的趋势。
{"title":"Use of patent information to characterize trends in the therapeutic applications of extracellular vesicles derived from mesenchymal stem cells (MSC-EVs).","authors":"Ángela Ponce-Polo, Alvaro RitoréHidalgo, Arturo Argüello Martínez, Roke Iñaki Oruezabal Guijarro","doi":"10.2174/1872208316666220303095217","DOIUrl":"https://doi.org/10.2174/1872208316666220303095217","url":null,"abstract":"Extracellular vesicles derived from mesenchymal stromal cells (MSC-EVs) are gaining interest for medical purposes. The promising therapeutic effects exhibited in both preclinical and clinical studies suggest that they may become an alternative for certain applications to cell-based therapies, which are subjected to stricter regulations. The commercial exploitation of these candidates requires a proper patent strategy from both the industry and public research organizations. Here, we raise a global patent literature analysis to identify key players and therapeutic applications in the field. Our results show an increasing rate of patent publications since 2009, with Asia (specifically China) leading the patenting activity. The therapeutic use of MSC-EVs within patent literature covers a wide range of diseases, in which \"Dermal and Wounds\", \"Neurology\" and \"Cardiovascular\" are the main therapeutic areas. Moreover, most of these patents include \"product-by-process\" claims, since the therapeutic effects of MSC-EVs could be influenced by their manufacturing process. Our results follow scientific and clinical literature trends.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47944454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges and approaches of drugs such as Memantine, Donepezil, Rivastigmine and Aducanumab in the treatment, control and management of Alzheimer's disease. 美金刚、多奈哌齐、利瓦斯蒂明和阿杜坎单抗等药物在阿尔茨海默病治疗、控制和管理中的挑战和方法。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-03-02 DOI: 10.2174/1872208316666220302115901
Mohammad Saeedi, F. Mehranfar
Alzheimer's disease (AD) is a kinds of neuropsychiatric illnesses that affect the central nervous system. In this disease, the accumulation of amyloid-beta increases, and phosphorylated tau (P-tau) protein, one of the ways to treat this disease is to reduce the accumulation of amyloid-beta. Various studies have demonstrated that pharmacological approaches have considerable effects in the treatment of AD, despite the side effects and challenges. Cholinesterase inhibitors and the NMDA receptor antagonist memantine are presently authorized therapies for AD. Memantine and Donepezil are the most common drugs for the prevention and therapy of AD with mechanisms such as lessened β-amyloid plaque, effect on N-Methyl-D-aspartate (NMDA) receptors. Diminution glutamate and elevated acetylcholine are some of the influences of medications administrated to treat AD, and drugs can also play a role in slowing the progression of cognitive and memory impairment. A new pharmacological approach and strategy is required to control the future of AD. This review appraises the effects of memantine, donepezil, rivastigmine, and aducanumab in clinical trials, in vitro and animal model studies that have explored how these drugs versus AD development and also discuss possible mechanisms of influence on the brain. Research in clinical trials has substantial findings that support the role of these medications in AD treatment and ameliorate the safety and efficacy of AD therapy, although more clinical trials are required to prove their effectiveness.
阿尔茨海默病(Alzheimer's disease, AD)是一种影响中枢神经系统的神经精神疾病。在这种疾病中,淀粉样蛋白- β的积累增加,并磷酸化tau (P-tau)蛋白,治疗这种疾病的方法之一是减少淀粉样蛋白- β的积累。各种研究表明,尽管存在副作用和挑战,但药物方法在治疗AD方面具有相当大的效果。胆碱酯酶抑制剂和NMDA受体拮抗剂美金刚目前被批准用于治疗阿尔茨海默病。美金刚和多奈哌齐是预防和治疗AD最常用的药物,其机制包括减少β-淀粉样斑块,影响n -甲基- d -天冬氨酸(NMDA)受体。谷氨酸减少和乙酰胆碱升高是治疗阿尔茨海默病的药物的一些影响,药物也可以在减缓认知和记忆障碍的进展中发挥作用。需要一种新的药理学方法和策略来控制AD的未来。本综述评估了美金刚、多奈哌齐、利瓦司明和阿杜坎单抗在临床试验、体外和动物模型研究中的作用,探讨了这些药物如何对抗AD的发展,并讨论了对大脑的可能影响机制。临床试验研究已经有了实质性的发现,支持这些药物在阿尔茨海默病治疗中的作用,改善了阿尔茨海默病治疗的安全性和有效性,尽管需要更多的临床试验来证明它们的有效性。
{"title":"Challenges and approaches of drugs such as Memantine, Donepezil, Rivastigmine and Aducanumab in the treatment, control and management of Alzheimer's disease.","authors":"Mohammad Saeedi, F. Mehranfar","doi":"10.2174/1872208316666220302115901","DOIUrl":"https://doi.org/10.2174/1872208316666220302115901","url":null,"abstract":"Alzheimer's disease (AD) is a kinds of neuropsychiatric illnesses that affect the central nervous system. In this disease, the accumulation of amyloid-beta increases, and phosphorylated tau (P-tau) protein, one of the ways to treat this disease is to reduce the accumulation of amyloid-beta. Various studies have demonstrated that pharmacological approaches have considerable effects in the treatment of AD, despite the side effects and challenges. Cholinesterase inhibitors and the NMDA receptor antagonist memantine are presently authorized therapies for AD. Memantine and Donepezil are the most common drugs for the prevention and therapy of AD with mechanisms such as lessened β-amyloid plaque, effect on N-Methyl-D-aspartate (NMDA) receptors. Diminution glutamate and elevated acetylcholine are some of the influences of medications administrated to treat AD, and drugs can also play a role in slowing the progression of cognitive and memory impairment. A new pharmacological approach and strategy is required to control the future of AD. This review appraises the effects of memantine, donepezil, rivastigmine, and aducanumab in clinical trials, in vitro and animal model studies that have explored how these drugs versus AD development and also discuss possible mechanisms of influence on the brain. Research in clinical trials has substantial findings that support the role of these medications in AD treatment and ameliorate the safety and efficacy of AD therapy, although more clinical trials are required to prove their effectiveness.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47012328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Insights into Novel Coronavirus Disease 2019 (COVID-19): Current Understanding, Research, and Therapeutic Updates. 洞察新型冠状病毒病2019 (COVID-19):当前的理解,研究和治疗更新。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-01-01 DOI: 10.2174/1872208315666210805152122
Dudala Sai Sushma, Varun Jaiswal, Arvind Kumar, Syed Asha, Tarun Pal

Background: Humans can be infected with various coronaviruses that can cause serious illness and death. One such pandemic strain of coronavirus was recently identified in December 2019, and it led to a devastating outbreak in Wuhan city of China. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2). It is highly contagious and causes symptoms such as fever, cough, and shortness of breath.

Objective: The objective of this review is to highlight the current understanding, research, and therapeutic updates of the novel coronavirus disease 2019 (COVID-19).

Methods: A thorough literature search was conducted for research papers and patents in the context of COVID-19. All the related articles were extracted from various public repositories such as Google Scholar, Pubmed, ScienceDirect (Elsevier), Springer, Web of Science, etc. Results: The present analysis revealed that the key areas of the inventions were vaccines and diagnostic kits apart from developing the treatment of CoV. It was also observed that no specific vaccine treatments were available for the treatment of 2019-nCov; therefore, developing novel chemical or biological drugs and kits for early diagnosis, prevention, and disease management is the primary governing topic among the patented inventions. The present study also indicates potential research opportunities for the future, particularly to combat 2019-nCoV. The current focus of the researches has turned towards developing four potential treatments, including the development of candidate vaccines, development of novel potential drugs, repurposing of existing drugs, and development of convalescent plasma therapy. The PCR based diagnosis is the gold standard for the COVID-19 testing, but it requires resource time, expertise, and high associated cost; hence researchers are also developing different diagnostic methods for the COVID-19. Although vaccines are being developed by various companies and have passed the pre-clinical stages but there still exists no guarantee for these to come into effect. The current treatments that are being used for COVID-19 patients are not well established and have shown limited success.

Conclusion: The pandemic has challenged the medical, economic, and public health infrastructure across the globe. There is an urgent need to explore all available and possible methods/ approaches to study this disease for drug and vaccine development at the earliest.

背景:人类可感染各种冠状病毒,这些病毒可导致严重疾病和死亡。最近在2019年12月发现了一种这样的大流行冠状病毒株,并导致了中国武汉市的毁灭性疫情。它是由严重急性呼吸综合征冠状病毒2 (SARS- CoV-2)引起的。它具有高度传染性,并引起发烧、咳嗽和呼吸短促等症状。目的:本综述的目的是强调目前对新型冠状病毒病2019 (COVID-19)的认识、研究和治疗进展。方法:全面查阅新冠肺炎相关的研究论文和专利。所有相关文章均从Google Scholar、Pubmed、ScienceDirect (Elsevier)、Springer、Web of Science等公共数据库中提取。结果:目前的分析显示,除了开发新型冠状病毒的治疗方法外,发明的重点领域是疫苗和诊断试剂盒。还观察到,没有针对2019-nCov的特异性疫苗治疗方法;因此,开发用于早期诊断、预防和疾病管理的新型化学或生物药物和试剂盒是专利发明的主要主题。本研究还指出了未来的潜在研究机会,特别是在对抗2019-nCoV方面。目前的研究重点已转向开发四种潜在的治疗方法,包括候选疫苗的开发、新型潜在药物的开发、现有药物的再利用和恢复期血浆治疗的开发。基于PCR的诊断是COVID-19检测的金标准,但它需要资源时间、专业知识和高昂的相关成本;因此,研究人员也在开发不同的新冠肺炎诊断方法。虽然疫苗正在由不同的公司开发,并已通过临床前阶段,但仍然没有保证这些疫苗会生效。目前用于COVID-19患者的治疗方法尚不完善,而且效果有限。结论:新冠肺炎疫情对全球医疗、经济和公共卫生基础设施构成了挑战。迫切需要探索所有可用的和可能的方法/途径来研究这种疾病,以便尽早开发药物和疫苗。
{"title":"Insights into Novel Coronavirus Disease 2019 (COVID-19): Current Understanding, Research, and Therapeutic Updates.","authors":"Dudala Sai Sushma,&nbsp;Varun Jaiswal,&nbsp;Arvind Kumar,&nbsp;Syed Asha,&nbsp;Tarun Pal","doi":"10.2174/1872208315666210805152122","DOIUrl":"https://doi.org/10.2174/1872208315666210805152122","url":null,"abstract":"<p><strong>Background: </strong>Humans can be infected with various coronaviruses that can cause serious illness and death. One such pandemic strain of coronavirus was recently identified in December 2019, and it led to a devastating outbreak in Wuhan city of China. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2). It is highly contagious and causes symptoms such as fever, cough, and shortness of breath.</p><p><strong>Objective: </strong>The objective of this review is to highlight the current understanding, research, and therapeutic updates of the novel coronavirus disease 2019 (COVID-19).</p><p><strong>Methods: </strong>A thorough literature search was conducted for research papers and patents in the context of COVID-19. All the related articles were extracted from various public repositories such as Google Scholar, Pubmed, ScienceDirect (Elsevier), Springer, Web of Science, etc. Results: The present analysis revealed that the key areas of the inventions were vaccines and diagnostic kits apart from developing the treatment of CoV. It was also observed that no specific vaccine treatments were available for the treatment of 2019-nCov; therefore, developing novel chemical or biological drugs and kits for early diagnosis, prevention, and disease management is the primary governing topic among the patented inventions. The present study also indicates potential research opportunities for the future, particularly to combat 2019-nCoV. The current focus of the researches has turned towards developing four potential treatments, including the development of candidate vaccines, development of novel potential drugs, repurposing of existing drugs, and development of convalescent plasma therapy. The PCR based diagnosis is the gold standard for the COVID-19 testing, but it requires resource time, expertise, and high associated cost; hence researchers are also developing different diagnostic methods for the COVID-19. Although vaccines are being developed by various companies and have passed the pre-clinical stages but there still exists no guarantee for these to come into effect. The current treatments that are being used for COVID-19 patients are not well established and have shown limited success.</p><p><strong>Conclusion: </strong>The pandemic has challenged the medical, economic, and public health infrastructure across the globe. There is an urgent need to explore all available and possible methods/ approaches to study this disease for drug and vaccine development at the earliest.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39279210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chitosan Oligomer and Zinc Oxide Nanoparticles for Treating Wastewaters: US20190134086 Patent Evaluation. 壳聚糖低聚物和氧化锌纳米颗粒处理废水:US20190134086专利评估。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-01-01 DOI: 10.2174/1872208315666211026104828
Fernanda Guimarães Valverde, Daniela Droppa-Almeida, Francine Ferreira Padilha

With the utilisation of algae, wastewater reuse is becoming a viable option for the energy industry, especially green energy. The growth of these algae in these wastewaters provides an alternative source for bioenergetics, however, the growth of other microorganisms can directly affect the production of bioenergy, requiring the removal and reduction of contaminants in these waters, in addition to being a source of contamination for workers. Therefore, the use of nanoparticles in bioremediation has been an alternative to mitigate the contamination of these wastewaters that have microorganisms capable of reducing the algae growth capacity. The objective of this work was to verify in the United States Patent and Trademarker office database (USPTO) patents that used chitosan nanoparticles as a form of wastewater treatment and to carry out the analysis of patent US20190134086, which addresses the use of zinc oxide nanoparticles associated with chitosan that was developed and used to evaluate their antibacterial activity against resistant microorganisms and biofilm producers present in wastewater. Escherichia coli, Enterococcus faecium, and/or Pseudomonas aeruginosa are the microorganisms involved in the evaluated invention, bacteria present in the gastrointestinal tract, of clinical and environmental importance. The synthesized nanoparticles are arranged as a pharmaceutically acceptable and toxic vehicle against resistant bacteria, thus being described as nanoremediators. Given the analyzed patent, it was possible to verify the importance of alternatives to reduce the impact that pollution, in general, has on the environment, in addition to the proposed technology serving to maintain the survival and development capacity of the algae that will be able to produce green energy, the nanoparticles with antibacterial potential can help indirectly reduce these pathogenic strains with resistance to several antibiotics in the environment.

随着藻类的利用,废水回用正成为能源工业,特别是绿色能源的可行选择。这些藻类在这些废水中的生长为生物能源提供了另一种来源,然而,其他微生物的生长可以直接影响生物能源的生产,这需要去除和减少这些水中的污染物,同时也是工人的污染源。因此,在生物修复中使用纳米颗粒是减轻这些废水污染的一种替代方法,这些废水中含有能够降低藻类生长能力的微生物。这项工作的目的是在美国专利和商标局数据库(USPTO)中验证使用壳聚糖纳米颗粒作为废水处理形式的专利,并对US20190134086专利进行分析,该专利涉及使用与壳聚糖相关的氧化锌纳米颗粒,该纳米颗粒被开发并用于评估其对废水中存在的耐药微生物和生物膜生产商的抗菌活性。大肠杆菌、屎肠球菌和/或铜绿假单胞菌是本发明所涉及的微生物,是存在于胃肠道中的细菌,具有临床和环境重要性。所合成的纳米颗粒被安排为抗耐药细菌的药学上可接受的毒性载体,因此被描述为纳米修复剂。鉴于所分析的专利,有可能验证替代方案的重要性,以减少污染对环境的影响,总的来说,除了拟议的技术有助于维持藻类的生存和发展能力,能够产生绿色能源,具有抗菌潜力的纳米颗粒可以间接帮助减少这些对环境中几种抗生素具有抗性的致病菌株。
{"title":"Chitosan Oligomer and Zinc Oxide Nanoparticles for Treating Wastewaters: US20190134086 Patent Evaluation.","authors":"Fernanda Guimarães Valverde,&nbsp;Daniela Droppa-Almeida,&nbsp;Francine Ferreira Padilha","doi":"10.2174/1872208315666211026104828","DOIUrl":"https://doi.org/10.2174/1872208315666211026104828","url":null,"abstract":"<p><p>With the utilisation of algae, wastewater reuse is becoming a viable option for the energy industry, especially green energy. The growth of these algae in these wastewaters provides an alternative source for bioenergetics, however, the growth of other microorganisms can directly affect the production of bioenergy, requiring the removal and reduction of contaminants in these waters, in addition to being a source of contamination for workers. Therefore, the use of nanoparticles in bioremediation has been an alternative to mitigate the contamination of these wastewaters that have microorganisms capable of reducing the algae growth capacity. The objective of this work was to verify in the United States Patent and Trademarker office database (USPTO) patents that used chitosan nanoparticles as a form of wastewater treatment and to carry out the analysis of patent US20190134086, which addresses the use of zinc oxide nanoparticles associated with chitosan that was developed and used to evaluate their antibacterial activity against resistant microorganisms and biofilm producers present in wastewater. Escherichia coli, Enterococcus faecium, and/or Pseudomonas aeruginosa are the microorganisms involved in the evaluated invention, bacteria present in the gastrointestinal tract, of clinical and environmental importance. The synthesized nanoparticles are arranged as a pharmaceutically acceptable and toxic vehicle against resistant bacteria, thus being described as nanoremediators. Given the analyzed patent, it was possible to verify the importance of alternatives to reduce the impact that pollution, in general, has on the environment, in addition to the proposed technology serving to maintain the survival and development capacity of the algae that will be able to produce green energy, the nanoparticles with antibacterial potential can help indirectly reduce these pathogenic strains with resistance to several antibiotics in the environment.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39563034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential Implications of Vouacapan Compounds for Insecticidal Activity: An In Silico Study. 对杀虫活性的潜在影响:一项硅研究。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-01-01 DOI: 10.2174/1872208316666220106110902
Lisset Ortiz-Zamora, Jaderson V Ferreira, Nayana K S de Oliveira, Fábio A de Molfetta, Lorane I S Hage-Melim, Caio P Fernandes, Anna E M F M Oliveira

Background: From the fruits and seeds of the species of Pterodon, it is possible to obtain two main products: essential oil and oleoresin. In oleoresin, numerous vouacapan compounds have been demonstrated to have biological potential, including insecticidal activity.

Objective: In silico studies were performed to identify potential candidates for natural insecticides among the vouacapans present in the genus Pterodon.

Materials and methods: Molecular docking and molecular dynamics studies were performed to analyze the interaction of vouacapan compounds with acetylcholinesterase of Drosophila melanogaster. Pharmacokinetic parameters regarding physicochemical properties, plasma protein binding, and activity in the central nervous system were evaluated. The toxicological properties of the selected molecules were predicted using malathion as the reference compound.

Results: 6α,7β-dimethoxivouacapan-17-ene (15) showed a high number of interactions and scores in molecular docking studies. These results suggested that this compound exhibits an inhibitory activity of the enzyme acetylcholinesterase. This compound showed the best results regarding physicochemical properties, besides presenting low cutaneous permeability values, suggesting null absorption. Molecular dynamics studies demonstrated few conformational changes in the structure of the complex formed by compound 4 and acetylcholinesterase enzyme throughout the simulation time.

Conclusion: It was determined that compound 4 (vouacapan 6α,7β,17β,19-tetraol) could be an excellent candidate for usage as a natural insecticide.

背景:从翼龙属植物的果实和种子中,可以获得两种主要产品:精油和油树脂。在油树脂中,已证明许多万年青化合物具有生物潜力,包括杀虫活性。目的:利用计算机研究方法,从翼龙属植物中鉴定潜在的天然杀虫剂候选物种。材料与方法:通过分子对接和分子动力学研究,分析了武卡潘类化合物与黑腹果蝇乙酰胆碱酯酶的相互作用。对其理化性质、血浆蛋白结合和中枢神经系统活性等药代动力学参数进行了评估。以马拉硫磷为参比化合物,预测了所选分子的毒理学性质。结果:6α,7β-dimethoxivouacapan-17-ene(15)在分子对接研究中表现出大量的相互作用和得分。这些结果表明,该化合物具有抑制乙酰胆碱酯酶的活性。该化合物在物理化学性能方面表现最好,除了具有低的皮肤渗透性值,表明零吸收。分子动力学研究表明,在整个模拟过程中,化合物4与乙酰胆碱酯酶形成的复合物结构几乎没有构象变化。结论:化合物4 (6α,7β,17β,19-四醇)是一种很有潜力的天然杀虫剂。
{"title":"Potential Implications of Vouacapan Compounds for Insecticidal Activity: An In Silico Study.","authors":"Lisset Ortiz-Zamora,&nbsp;Jaderson V Ferreira,&nbsp;Nayana K S de Oliveira,&nbsp;Fábio A de Molfetta,&nbsp;Lorane I S Hage-Melim,&nbsp;Caio P Fernandes,&nbsp;Anna E M F M Oliveira","doi":"10.2174/1872208316666220106110902","DOIUrl":"https://doi.org/10.2174/1872208316666220106110902","url":null,"abstract":"<p><strong>Background: </strong>From the fruits and seeds of the species of Pterodon, it is possible to obtain two main products: essential oil and oleoresin. In oleoresin, numerous vouacapan compounds have been demonstrated to have biological potential, including insecticidal activity.</p><p><strong>Objective: </strong>In silico studies were performed to identify potential candidates for natural insecticides among the vouacapans present in the genus Pterodon.</p><p><strong>Materials and methods: </strong>Molecular docking and molecular dynamics studies were performed to analyze the interaction of vouacapan compounds with acetylcholinesterase of Drosophila melanogaster. Pharmacokinetic parameters regarding physicochemical properties, plasma protein binding, and activity in the central nervous system were evaluated. The toxicological properties of the selected molecules were predicted using malathion as the reference compound.</p><p><strong>Results: </strong>6α,7β-dimethoxivouacapan-17-ene (15) showed a high number of interactions and scores in molecular docking studies. These results suggested that this compound exhibits an inhibitory activity of the enzyme acetylcholinesterase. This compound showed the best results regarding physicochemical properties, besides presenting low cutaneous permeability values, suggesting null absorption. Molecular dynamics studies demonstrated few conformational changes in the structure of the complex formed by compound 4 and acetylcholinesterase enzyme throughout the simulation time.</p><p><strong>Conclusion: </strong>It was determined that compound 4 (vouacapan 6α,7β,17β,19-tetraol) could be an excellent candidate for usage as a natural insecticide.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39794852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Powerful Stress Relieving Medicinal Plants for Anger, Anxiety, Depression, and Stress During Global Pandemic. 强大的压力缓解药用植物愤怒,焦虑,抑郁,压力在全球大流行。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-01-01 DOI: 10.2174/1872208316666220321102216
Mohamad Hesam Shahrajabian

Consideration and improvement for anxiety and depression are important during a global pandemic. Appropriate healthcare can be obtained by paying more attention to traditional medicinal sciences. The adverse effects of stress with various symptoms can be managed by introducing plants that boost mental health. The most relevant psychological reactions in the general population related to the global pandemic are pervasive anxiety, frustration and boredom, specific and uncontrolled fear, disabling loneliness, significant lifestyle changes, and psychiatric conditions. Ginseng, chamomile, passionflower, herbal tea, lavender, saffron, kava, rose, cardamom, Chinese date, and some chief formula like yokukansan, Dan-zhi-xiao-yao-san, so-ochim-tang-gamiband, and saikokaryukotsuboreito are notable herbal treatments for mental health problems. The most common medicinal plants that have been used in Iran for the cure of stress and anxiety are Viper's-buglosses, Dracocephalum, valerian, chamomile, common hop, hawthorns, and lavender. Medicinal plants and herbs can be used for the treatment and alleviation of the negative effects of stress, anger, and depression during the global pandemic.

在全球大流行期间,考虑和改善焦虑和抑郁是很重要的。通过更多地关注传统医学,可以获得适当的医疗保健。压力带来的各种症状的不利影响可以通过引入促进心理健康的植物来控制。与全球大流行相关的普通人群中最相关的心理反应是普遍的焦虑、沮丧和无聊、特定和不受控制的恐惧、致残的孤独、重大的生活方式改变和精神状况。人参、洋甘菊、西番莲、凉茶、薰衣草、藏红花、卡瓦、玫瑰、小豆蔻、红枣,以及一些主要配方,如yokukansan、danzhixiayao -san、soochim - tangang -gamiband和saikokaryukotsuboreito,都是治疗心理健康问题的著名草药。在伊朗,用于治疗压力和焦虑的最常见药用植物是毒蛇草、龙头草、缬草、洋甘菊、普通啤酒花、山楂和薰衣草。在全球大流行期间,药用植物和草药可用于治疗和减轻压力、愤怒和抑郁的负面影响。
{"title":"Powerful Stress Relieving Medicinal Plants for Anger, Anxiety, Depression, and Stress During Global Pandemic.","authors":"Mohamad Hesam Shahrajabian","doi":"10.2174/1872208316666220321102216","DOIUrl":"https://doi.org/10.2174/1872208316666220321102216","url":null,"abstract":"<p><p>Consideration and improvement for anxiety and depression are important during a global pandemic. Appropriate healthcare can be obtained by paying more attention to traditional medicinal sciences. The adverse effects of stress with various symptoms can be managed by introducing plants that boost mental health. The most relevant psychological reactions in the general population related to the global pandemic are pervasive anxiety, frustration and boredom, specific and uncontrolled fear, disabling loneliness, significant lifestyle changes, and psychiatric conditions. Ginseng, chamomile, passionflower, herbal tea, lavender, saffron, kava, rose, cardamom, Chinese date, and some chief formula like yokukansan, Dan-zhi-xiao-yao-san, so-ochim-tang-gamiband, and saikokaryukotsuboreito are notable herbal treatments for mental health problems. The most common medicinal plants that have been used in Iran for the cure of stress and anxiety are Viper's-buglosses, Dracocephalum, valerian, chamomile, common hop, hawthorns, and lavender. Medicinal plants and herbs can be used for the treatment and alleviation of the negative effects of stress, anger, and depression during the global pandemic.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40314731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Evaluating Five Escherichia coli Derivative Strains as a Platform for Arginine Deiminase Overproduction. 评价5种大肠杆菌衍生菌株作为精氨酸脱亚胺酶过量生产的平台。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2022-01-01 DOI: 10.2174/1872208315666211122114625
Sara Abdollahi, Mohammad Hossein Morowvat, Amir Savardashtaki, Cambyz Irajie, Sohrab Najafipour, Younes Ghasemi

Aims: This study attempted to evaluate the five host strains, including BL21 (DE3), Rosetta (DE3), DH5α, XL1-BLUE, and SHuffle, in terms of arginine deiminase (ADI) production and enzyme activity.

Background: Escherichia coli is one of the most preferred host microorganisms for the production of recombinant proteins due to its well-characterized genome, availability of various expression vectors, and host strains. Choosing a proper host strain for the overproduction of a desired recombinant protein is very important because of the diversity of genetically modified expression strains. Various E. coli cells have been examined in different patent applications.

Methods: ADI was chosen as a bacterial enzyme that degrades L-arginine. It is effective in the treatment of some types of human cancers like melanoma and hepatocellular carcinoma (HCC), which are arginine-auxotrophic. Five mentioned E. coli strains were cultivated. The pET-3a was used as the expression vector. The competent E. coli cells were obtained through the CaCl2 method. It was then transformed with the construct of pET3a-ADI using the heat shock strategy. The ADI production levels were examined by 10% SDS-PAGE analysis. The ability of host strains for the expression of the requested recombinant protein was compared. The enzymatic activity of the obtained recombinant ADI from each studied strain was assessed by a colorimetric 96-well microtiter plate assay.

Results: All the five strains exhibited a significant band at 46 kDa. BL21 (DE3) produced the highest amount of ADI protein, followed by Rosetta (DE3). The following activity assay showed that ADI from BL21 (DE3) and Rosetta (DE3) had the most activity.

Conclusion: There are some genetic and metabolic differences among the various E. coli strains, leading to differences in the amount of recombinant protein production. The results of this study can be used for the efficacy evaluation of the five studied strains for the production of similar pharmaceutical enzymes. The strains also could be analyzed in terms of proteomics.

目的:对5株寄主菌株BL21 (DE3)、Rosetta (DE3)、DH5α、XL1-BLUE和SHuffle的精氨酸脱亚胺酶(ADI)产量和酶活性进行评价。背景:大肠杆菌是生产重组蛋白的首选宿主微生物之一,因为它具有良好的基因组特征,各种表达载体的可用性和宿主菌株。由于基因修饰表达菌株的多样性,选择合适的宿主菌株来过量生产所需的重组蛋白是非常重要的。各种大肠杆菌细胞在不同的专利申请中得到了检验。方法:选择ADI作为降解l -精氨酸的细菌酶。它对某些类型的人类癌症有效,如黑色素瘤和肝细胞癌(HCC),这是精氨酸营养不良。培养了上述5株大肠杆菌。以pET-3a为表达载体。通过CaCl2法获得了能态大肠杆菌细胞。然后使用热休克策略将其转化为pET3a-ADI结构。通过10% SDS-PAGE分析检测ADI的生产水平。比较了不同寄主菌株表达重组蛋白的能力。通过96孔微滴板比色法测定从每个研究菌株获得的重组ADI的酶活性。结果:5株菌株均在46 kDa处出现显著条带。BL21 (DE3)产生ADI蛋白量最高,其次是Rosetta (DE3)。随后的活性测定表明,BL21 (DE3)和Rosetta (DE3)的ADI活性最高。结论:不同大肠杆菌菌株之间存在一定的遗传和代谢差异,从而导致重组蛋白产量的差异。本研究结果可用于评价所研究菌株生产类似药用酶的功效。菌株也可以进行蛋白质组学分析。
{"title":"Evaluating Five Escherichia coli Derivative Strains as a Platform for Arginine Deiminase Overproduction.","authors":"Sara Abdollahi,&nbsp;Mohammad Hossein Morowvat,&nbsp;Amir Savardashtaki,&nbsp;Cambyz Irajie,&nbsp;Sohrab Najafipour,&nbsp;Younes Ghasemi","doi":"10.2174/1872208315666211122114625","DOIUrl":"https://doi.org/10.2174/1872208315666211122114625","url":null,"abstract":"<p><strong>Aims: </strong>This study attempted to evaluate the five host strains, including BL21 (DE3), Rosetta (DE3), DH5α, XL1-BLUE, and SHuffle, in terms of arginine deiminase (ADI) production and enzyme activity.</p><p><strong>Background: </strong>Escherichia coli is one of the most preferred host microorganisms for the production of recombinant proteins due to its well-characterized genome, availability of various expression vectors, and host strains. Choosing a proper host strain for the overproduction of a desired recombinant protein is very important because of the diversity of genetically modified expression strains. Various E. coli cells have been examined in different patent applications.</p><p><strong>Methods: </strong>ADI was chosen as a bacterial enzyme that degrades L-arginine. It is effective in the treatment of some types of human cancers like melanoma and hepatocellular carcinoma (HCC), which are arginine-auxotrophic. Five mentioned E. coli strains were cultivated. The pET-3a was used as the expression vector. The competent E. coli cells were obtained through the CaCl2 method. It was then transformed with the construct of pET3a-ADI using the heat shock strategy. The ADI production levels were examined by 10% SDS-PAGE analysis. The ability of host strains for the expression of the requested recombinant protein was compared. The enzymatic activity of the obtained recombinant ADI from each studied strain was assessed by a colorimetric 96-well microtiter plate assay.</p><p><strong>Results: </strong>All the five strains exhibited a significant band at 46 kDa. BL21 (DE3) produced the highest amount of ADI protein, followed by Rosetta (DE3). The following activity assay showed that ADI from BL21 (DE3) and Rosetta (DE3) had the most activity.</p><p><strong>Conclusion: </strong>There are some genetic and metabolic differences among the various E. coli strains, leading to differences in the amount of recombinant protein production. The results of this study can be used for the efficacy evaluation of the five studied strains for the production of similar pharmaceutical enzymes. The strains also could be analyzed in terms of proteomics.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39736846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Recent patents on biotechnology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1